Intervention

IDP-023

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 1 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials1

Recruiting0

Common conditions11

Lead sponsors shown1

Clinical trials

1 shown

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30

SUSPENDED

Common conditions

Autoimmune Diseases1 Autoimmune Diseases of the Nervous System1 Demyelinating Autoimmune Diseases, Central Nervous System (CNS)1 Demyelinating Diseases1 Immune System Diseases1 Multiple Sclerosis1 Nervous System Diseases1 Non-Active Secondary Progressive Multiple Sclerosis1 Non-Active SPMS1 Primary Progressive Multiple Sclerosis (PPMS)1 Secondary Progressive Multiple Sclerosis (SPMS)1

Leading sponsors

Indapta Therapeutics, INC. 1

Trial status mix

SUSPENDED1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.